GTx, Inc. (GTXI) to Present Preclinical Data on a New Therapeutic Target in Prostate Cancer

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) announced today that new preclinical data will be presented indicating that AKR1C3, a steroidogenic enzyme, is an androgen receptor-selective coactivator and promoter of growth in prostate cancer cells and castration resistant prostate cancer (CRPC), and may represent the first nuclear hormone receptor coactivator that can be pharmacologically targeted in the treatment of advanced prostate cancer. The presentation will be given by Dr. Ramesh Narayanan, Director, Drug Discovery for GTx, Inc. on February 14 at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancer Symposium in Orlando, Florida.